The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion…
Author: BioSpace
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in…
High profile failures and long timeframes for revenue have shifted investment away from Phase I, as VCs seek to mitigate…
Following a 90% drop in share price due to an FDA rejection and a warning letter over Applied Therapeutics’ conduct…
Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists also show potential in several other indications, including…
Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome…
This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie,…
Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the…
Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its…
First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in…